

Datasheet



Mouse mAb to **CD56**
Clone **EBS-CD-033**
Isotype **IgG1-κ**

Source

A BALB/c mouse was immunized with a crude membrane preparation of a small cell lung cancer.
Fusion partner: SP2/0.

Specifications

EBS-CD-033 reacts with an extracellular domain (close to the cell membrane) of CD56/NCAM. Only 2 isoforms of NCAM are recognized by EBS-CD-033 (180 kDa and 145 kDa). EBS-CD-033 was used successfully for immunoscintigraphy and immunotherapy of SCLC xenografts in nude mice. EBS-CD-033 recognizes NCAM in retinoblastoma, medulloblastomas, astrocytomas, neuroblastomas, and small cell lung carcinomas. NCAM is also expressed on some mesodermally derived tumors (a.o. rhabdomyosarcoma). Anti-CD56 plays an important role in the diagnosis of nodal and nasal NK/T-cell lymphomas.




Figure 1: Human colon ganglion stained with EBS-CD-033 (paraffin).

Species reactivity

Positive: human.

Applications

Differential diagnosis involving neuroectodermally derived tumors e.g. retinoblastoma, medulloblastomas, astrocytomas, neuroblastomas, small cell carcinomas, but also NK/T-cell lymphomas.

ELISA	Flow cytometry	Frozen sections	Immunofluorescence	Paraffin sections	Western blotting
+	+	+	+	Citrate	+

Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.

Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

Dilution advice

- ELISA (solid phase; not known; tracer: 0,001-100 µg/ml for 30 min at RT).
- Flow cytometry (0,5-1,0 µg/million cells in 0,1 ml).
- Immunoblotting (1-2 µg/ml).
- Immunofluorescence (0,5-1,0 µg/ml).
- Immunohistology (formalin-fixed: 1-2 µg/ml for 30 min at RT; staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6,0, for 10-20 min followed by cooling at RT for 20 minutes).

Positive control

Cerebellum, pancreas, neuroblastoma.

Datasheet



References

- Schol DJ. et al, *Int. J. Cancer* **Suppl.2**: 35-40 (1988).
- Moolenaar KE. et al, *Cancer Res.* **50**: 1102-1106 (1990).
- Mooi WJ. et al, *Mol. and Cel. Probes* **2**: 31-37 (1988).
- Kibbelaar RE. et al, *Eur J Cancer* **27(4)**: 431-5 (1991).
- Skov BG. et al, *Br J Cancer* **Suppl. 14**: 46-8 (1991).
- Brezicka FT. et al, *APMIS.* **99(9)**: 797-802 (1991).
- Gerardy-Schahn R. et al. *Int J Cancer* **Suppl. 8**: 38-42 (1994).
- Kaufman O. et al, *Hum. Pathol.* **28(12)**: 1373-1378 (1997).
- Kwa HB. et al. *Br. J. Cancer* **73**: 439-446 (1996).
- Tsang WY. et al, *Am. J. Surg. Pathol.* **20(2)**: 202-210 (1996).
- Lantuéjoul S. et al, *Hum. Pathol.* **31(4)**: 415-21 (2000).
- Takaku H. et al. *Am J Gastroenterol.* **94(5)**: 1402-4 (1999).
- Michalides R. et al. *Int. J. Cancer* **Suppl. 8**: 34-7 (1994).
- Beverly et al, *Lung Cancer* **4**: 15-36 (1988).
- Souhami RL. et al, *Lancet* **2**: 325-326 (1987).
- Christopher MG. et al, *Cytojournal* **8**: 7 (2011).
- Langdon SP. et al. *Cancer Res.* **48(21)**: 6161-65 (1988).
- Langdon SP. et al. *Cancer Res.* **48(21)**: 6166-72 (1988).